EGFR and non-small cell lung carcinoma: Compared to non-targeted therapies for EGFR-mutated NSCLC, such as standard or platinum-based chemotherapy, patients receiving either first (gefitinib) or third generation (osimertinib) EGFR-TKIs as first-line treatments showed significantly longer median PFS of 9.2 months (95% CI 9.1-11) and 18.9 months (95% CI 15.2-21.4), respectively, and superior OS (Fig. 3a; Supplementary Table 2).